Pharmaceutical Contract Manufacturing
News and Media
UPM PHARMACEUTICALS®, INC. ANNOUNCES API DIRECT-FILL CAPABILITIES
Baltimore, MD, August 21, 2007 – UPM Pharmaceuticals®, Inc., reports extraordinary interest in it's newly purchased Xcelodose™ 600 System since installation and qualification earlier this year. This state-of-the-art equipment reduces early stage formulation activities because capsules can be filled solely with the drug substance. The addition of the Xcelodose™ 600 System to UPM’s expanding range of capabilities will allow the company to offer clients a way to shorten their time through the drug development process. The Xcelodse 600 is fully automated avoiding the inaccuracies associated with hand-filling, and can fill doses as low as 100 ug. This technology reduces the time taken to reach the ‘first in humans’ clinical trial decision point, which allows an increase in throughput of candidate compounds for development.
UPM Pharmaceuticals®, Inc. is a Baltimore-based, independent pharmaceutical company that provides product development and manufacturing services to pharmaceutical and biotechnology companies. UPM’s scientists use state-of-the-art technological approaches to solve challenging early stage pharmaceutical product design and formulation problems. Their services include: formulation development and optimization; cGMP manufacture of clinical trial materials; blinding of clinical supplies; analytical methods development and validation; ICH Stability studies; scale-up and technology transfer; and regulatory support. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries.
For more information, visit www.upm-inc.com and the UPM Pharmaceuticals®, Inc., exhibit (#1501) at the AAPS Annual Meeting in San Diego, November 11-15, 2007.
Contact:
Fran Spaven: 410.843.3719
Sara Mathew: 425.322.5866
UPM Pharmaceuticals®, Inc.
6200 Seaforth Street, Baltimore, MD 21224
Phone: 410.843.3700
Fax: 410.633.4438
10/25/06 - UPM PHARMACEUTICALS®, INC. PREPARES TO UNDERGO PAI INSPECTION
Baltimore, MD, October 25, 2006 – UPM Pharmaceuticals®, Inc., an FDA registered, inspected and cGMP compliant CRO, announced today that it is presently completing an extensive compliance enhancement program in support of commercial manufacturing and FDA PAI (pre-approval inspection) readiness. These business initiatives broaden UPM's services and capabilities allowing clients to work with a single company from early stage formulation development to product scale up and commercialization.
UPM Pharmaceuticals®, Inc. is a Baltimore-based, independent pharmaceutical company that provides product development and manufacturing services to pharmaceutical and biotechnology companies. UPM’s scientists use state-of-the-art technological approaches to solve challenging early stage pharmaceutical product design and formulation problems. Their services include: formulation development and optimization; cGMP manufacture of clinical trial materials; blinding of clinical supplies; analytical methods development and validation; ICH Stability studies; scale-up and technology transfer; and regulatory support. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries.
For more information, visit www.upm-inc.com and the UPM Pharmaceuticals®, Inc., exhibit (#1524) at the AAPS Annual Meeting in San Antonio, October 29-November 2, 2006.
03/03/06 - UPM PHARMACEUTICALS™, INC. IS PREPARED TO MEET THE FUTURE WITH RECENT UPGRADES AND PERSONNEL EXPANSIONS
UPM Dramatically Enhances Their Research and Manufacturing Capabilities: $4 Million Invested In Capital Equipment
Baltimore, MD, March 3, 2006 - UPM Pharmaceuticals, Inc. is set to enter a new era of company versatility & growth, as evidenced by a growing inventory of state-of-the-art equipment designed to produce a variety of pharmaceutical solid dosage forms. In the past 15 months, the company has invested over $4,000,000 in capital equipment designed to dramatically enhance their research & development and small scale commercial manufacturing production capabilities. Recent purchases include equipment to facilitate fluid bed technology, tableting & capsule filling, over encapsulation, granulating, drying, and controlled release drug delivery. Purchased from leading worldwide pharmaceutical process equipment manufacturers, this equipment includes the latest process control technology. Key equipment upgrades include: Glatt GPCG2 Fluid Bed Processor; Fette 1200i Tablet Press; MG2 Planeta 50 Capsule Filler; and Glatt GPCG30 Fluid Bed Processor.
UPM Hires New Staff To Lead Analytical And Manufacturing Technologies
The company has seen simultaneous growth in terms of personnel, who have been brought on board to focus on the company's goals for advanced formulation development and manufacturing technologies. Founded in 1997, UPM currently has over 40 employees. Ruth Moore, Ph.D. has recently been hired as Executive Director, Laboratory Services for UPM Pharmaceuticals, Inc. Dr. Moore has over 15 years experience providing research and development laboratory services to pharmaceutical & related industries. She has spent the last 10 years leading formulations, methods development, validation, and stability programs in support of drug development and manufacture. UPM Pharmaceuticals, Inc. also recently welcomed Edward Scholtz, Ph.D. to the position of Vice President of Research & Development. Dr. Scholtz has over 20 years with Merck & Co., Inc. His industry experience ranges from formulation development, process scale-up, clinical study design, compliance, and manufacturing rollouts.
John Gregory, CEO & Chairman of the Board of UPM Pharmaceuticals, inc. said "Our company is committed to growth and expansion of the technical capabilities and services that we provide to our pharmaceutical clients. This investment in superior equipment and senior leadership takes UPM to a new level that is exciting for our company and, we hope, equally invigorating for our clients." UPM Pharmaceuticals, Inc. is a Baltimore-based, independent pharmaceutical company that provides product development and manufacturing services to pharmaceutical and biotechnology companies.
UPM's scientists use state-of-the-art technological approaches to solve challenging early stage pharmaceutical product design & formulation problems. Their services include: formulation process development & optimization; cGMP manufacture of clinical trial materials; blinding of clinical supplies; analytical methods development and validation; ICH Stability studies; scale-up and technology transfer; and regulatory support. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries. For more information about UPM Pharmaceuticals, Inc. visit www.upm-inc.com and their exhibit at the BIO 2006 Annual International Convention in Chicago, April 9-12, 2006.
05/04/04 - FDA Inspection
On March 1 - 4, 2004, the Food & Drug Administration (FDA) conducted an inspection of the facilities of UPM Pharmaceuticals, Inc. (UPM), a contract manufacturer of pharmaceuticals (including formulation development) used in Phase 1, 2, and 3 clinical trials. UPM is pleased to announce that the results of that inspection were classified as No Action Indicated (NAI); there were no FDA-483 citations issued. By virtue of these inspection results, UPM has expanded their production of clinical study materials for Phase III clinical studies, and is moving forward with plans to become a registered facility for commercial drug product manufacturing.